Vikram Anand

Vikram Anand

Auto-generated profile, based on publicly available information

Vikram Anand

Division of Infectious Diseases, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MXMichael W. Xie
Michael W. Xie
FJFulai Jin
Fulai Jin
HHHeejun Hwang
Heejun Hwang
SHSeungmin Hwang
Seungmin Hwang
VAVikram Anand
Vikram Anand
JHJing Huang
Jing Huang
With the advent of complete genome sequences, large-scale functional analyses are generating new excitement in biology and medicine. To facilitate genomewide functional analyses, we developed a high-density cell array with quantitative and automated readout of cell fitness. Able to print at >×10 higher density on a standard microtiter plate area than currently possible, our cell array allows single-plate screening of the complete set of Saccharomyces cerevisiae gene-deletion library and significantly reduces the amount of small molecules and other materials needed for the study. We used this method to map the relation between genes and cell fitness in response to rapamycin, a medically important natural product that targets the eukaryotic kinase Tor. We discuss the implications for pharmacogenomics and the uncharted complexity in genotype-dependent drug response in molecularly targeted therapies. Our analysis leads to several basic findings, including a class of gene deletions that confer better fitness in the presence of rapamycin. This result provides insights into possible therapeutic uses of rapamycin/CCI-779 in the treatment of neurodegenerative diseases (including Alzheimer's, Parkinson's, and Huntington's diseases), and cautions the possible existence of similar rapamycin-enhanceable mutations in cancer. It is well established in yeast that although TOR2 has a unique rapamycin-insensitive function, TOR1 and TOR2 are interchangeable in the rapamycin-sensitive functions. We show that even the rapamycin-sensitive functions are distinct between TOR1 and TOR2 and map the functional difference to a ≈120-aa region at the N termini of the proteins. Finally, we discuss using cell-based genomic pattern recognition in designing electronic or optical biosensors.

8 January 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EKE. Kakkis
E. Kakkis
TLT. Lester
T. Lester
RYR. Yang
R. Yang
CTC. Tanaka
C. Tanaka
VAV. Anand
V. Anand
MPM. Passage
M. Passage
Immune responses can interfere with the effective use of therapeutic proteins to treat genetic deficiencies and have been challenging to manage. To address this problem, we adapted and studied methods of immune tolerance used in canine organ transplantation research to soluble protein therapeutics. A tolerization regimen was developed that prevents a strong antibody response to the enzyme α-l-iduronidase during enzyme replacement therapy of a canine model of the lysosomal storage disorder mucopolysaccharidosis I. The tolerizing regimen consists of a limited 60-day course of cyclosporin A and azathioprine combined with weekly i.v. infusions of low-dose recombinant human α-l-iduronidase. The canines tolerized with this regimen maintain a reduced immune response for up to 6 months despite weekly therapeutic doses of enzyme in the absence of immunosuppressive drugs. Successful tolerization depended on high plasma levels of cyclosporin A combined with azathioprine. In addition, the induction of tolerance may require mannose 6-phosphate receptor-mediated uptake because α-l-iduronidase and α-glucosidase induced tolerance with the drug regimen whereas ovalbumin and dephosphorylated α-l-iduronidase did not. This tolerization method should be applicable to the treatment of other lysosomal storage disorders and provides a strategy to consider for other nontoleragenic therapeutic proteins and autoimmune diseases.

1 March 2009 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
VAVikram C. Anand
Vikram C. Anand
LDLydia Daboussi
Lydia Daboussi
TLTodd C. Lorenz
Todd C. Lorenz
GPGregory S. Payne
Gregory S. Payne
The evolutionarily conserved adaptor protein-3 (AP-3) complex mediates cargo-selective transport to lysosomes and lysosome-related organelles. To identify proteins that function in AP-3–mediated transport, we performed a genome-wide screen in Saccharomyces cerevisiae for defects in the vacuolar maturation of alkaline phosphatase (ALP), a cargo of the AP-3 pathway. Forty-nine gene deletion strains were identified that accumulated precursor ALP, many with established defects in vacuolar protein transport. Maturation of a vacuolar membrane protein delivered via a separate, clathrin-dependent pathway, was affected in all strains except those with deletions of YCK3, encoding a vacuolar type I casein kinase; SVP26, encoding an endoplasmic reticulum (ER) export receptor for ALP; and AP-3 subunit genes. Subcellular fractionation and fluorescence microscopy revealed ALP transport defects in yck3Δ cells. Characterization of svp26Δ cells revealed a role for Svp26p in ER export of only a subset of type II membrane proteins. Finally, ALP maturation kinetics in vac8Δ and vac17Δ cells suggests that vacuole inheritance is important for rapid generation of proteolytically active vacuolar compartments in daughter cells. We propose that the cargo-selective nature of the AP-3 pathway in yeast is achieved by AP-3 and Yck3p functioning in concert with machinery shared by other vacuolar transport pathways.

1 December 2016 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
VAVikram Anand
Vikram Anand
JHJenna Holmen
Jenna Holmen
MNMichael Neely
Michael Neely
PPPia S. Pannaraj
Pia S. Pannaraj
JBJennifer Dien Bard
Jennifer Dien Bard

22 May 2020 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
MPMimi R Precit
Mimi R Precit
RYRebecca Yee
Rebecca Yee
VAVikram Anand
Vikram Anand
KMKanokporn Mongkolrattanothai
Kanokporn Mongkolrattanothai
UPUtsav Pandey
Utsav Pandey
JBJennifer Dien Bard
Jennifer Dien Bard

28 August 2019 in Lung
Verified
Journal Article
Closed access
PDF file
MAMuhanned Abu-Hijleh
Muhanned Abu-Hijleh
KSKim Styrvoky
Kim Styrvoky
VAVikram Anand
Vikram Anand
FWFernando Woll
Fernando Woll
LYLonny Yarmus
Lonny Yarmus
DWDouglas E. Wood
Douglas E. Wood